Evidence map›Paper›PMID 42454703›Full record

ArticleAngewandte Chemie (International ed. in English)2026

"Alkaline-Hammer Strategy" Breaks Acidic and Stromal Barriers to Induce Alkaliptosis and Enhance Immunotherapy in Pancreatic Cancer.

Wei Liu, Yilong Li, Kuo He, Wenda Jiang, Jiajun Li, Xin Zheng, Qiyuan Li, Tieyuan Sun, Jialin Ren, Jixin Liang and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Wei LiuDepartment of Pancreatic and Biliary Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Yilong LiDepartment of Pancreatic and Biliary Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Kuo HeKey Laboratory of Rare Earth Resource Utilization, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin, China.
Wenda JiangKey Laboratory of Hepatosplenic Surgery, Ministry of Education, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Jiajun LiDepartment of Pancreatic and Biliary Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Xin ZhengDepartment of Pancreatic and Biliary Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Qiyuan LiDepartment of Pancreatic and Biliary Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Tieyuan SunDepartment of Pancreatic and Biliary Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Jialin RenDepartment of Pancreatic and Biliary Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Jixin LiangDepartment of Pancreatic and Biliary Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Hua ChenDepartment of Pancreatic and Biliary Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Yongwei WangDepartment of Pancreatic and Biliary Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Chunfa YangDepartment of Pancreatic and Biliary Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Jiandong WuKey Laboratory of Hepatosplenic Surgery, Ministry of Education, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Bei SunDepartment of Pancreatic and Biliary Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.ORCID 0000-0001-6688-2294
Xinlong WangDepartment of Pancreatic and Biliary Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.ORCID 0000-0001-6076-2822
Ping'an MaKey Laboratory of Rare Earth Resource Utilization, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin, China.ORCID 0000-0003-4198-5240

Funding

China Postdoctoral Science Foundation 2024MD763973Heilongjiang Provincial Natural Science Foundation of Outstanding Youth YQ2024H010Heilongjiang Touyan Innovation Team Program TY24003Major Project of the State Key Laboratory in Changchun 23GZZ04National Natural Science Foundation of China 82270665National Natural Science Foundation of China 82470672National Natural Science Foundation of China 82573335National Science and Technology Major Project 2024ZD0525500National Science and Technology Major Project 2024ZD0525503Natural Science Foundation of Heilongjiang Province QC2025H008Outstanding Youth Funds of the First Affiliated Hospital of Harbin Medical University 2024JQ17Project of Key Research and Development Program (Innovation Base) of Heilongjiang Province JD2023SJ42the Key Program of Natural Science Foundation of Heilongjiang Province ZL2025H004
6 · The paper itself

Abstract

Immunotherapy for pancreatic cancer remains a formidable challenge due to the highly immunosuppressive tumor microenvironment (TME), characterized by dense stromal barriers and acidic niches that collectively restrict drug delivery and antitumor immunity. Here, we propose an "Alkaline-Hammer" strategy that combines pH modulation with alkaliptosis induction to overcome these obstacles. We engineered alkalizing sodium bicarbonate nanoparticles (JTC801-NaHCO

Indexed as

Antineoplastic AgentsImmunotherapyPancreatic NeoplasmsSodium BicarbonateAnimalsCarbonic Anhydrase IXCell Line, TumorHumansHydrogen-Ion ConcentrationMiceNanoparticlesTumor MicroenvironmentAntineoplastic AgentsCarbonic Anhydrase IXSodium BicarbonatealkaliptosisCA9ICDimmunotherapypancreatic cancerTME

Identifiers

PMID42454703
PMCPMC13573107

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.